.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ01_Exenatide.Exenatide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BJ01_Exenatide.Exenatide| name: | Exenatide | |
| ATC code: | A10BJ01 | route: | subcutaneous |
| compartments: | 2 | |
| dosage: | 10 | mg |
| volume of distribution: | 28.3 | L |
| clearance: | 9.1 | L/h |
| other parameters in model implementation | ||
Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is available in both twice-daily injection (Byetta) and long-acting once-weekly (Bydureon) formulations. Exenatide is approved and widely used today.
Pharmacokinetic parameters reported from healthy subjects and patients with type 2 diabetes after subcutaneous administration of 5 or 10 mcg exenatide. Single- and multiple-dose two-compartment models have been used. Data below reflect findings from key clinical studies and FDA labeling references.
Cirincione, B, & Mager, DE (2017). Population pharmacokinetics of exenatide. British journal of clinical pharmacology 83(3) 517–526. DOI:10.1111/bcp.13135 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27650681
Cirincione, B, et al., & Mager, DE (2017). Population Pharmacokinetics of an Extended-Release Formulation of Exenatide Following Single- and Multiple-Dose Administration. The AAPS journal 19(2) 487–496. DOI:10.1208/s12248-016-9975-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27896683
Zhao, X, et al., & Soon, D (2008). Exenatide pharmacokinetics in healthy Chinese subjects. International journal of clinical pharmacology and therapeutics 46(9) 459–465. DOI:10.5414/cpp46459 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18793576